STAC2 Antibody

What is STAC2 and what biological functions does it perform?

STAC2 is a protein that functions as a critical regulator of excitation-contraction coupling in skeletal muscle cells, playing a key role in communication between the voltage-sensing dihydropyridine receptor (DHPR) and the calcium release channel ryanodine receptor (RyR). Dysregulation of STAC2 has been linked to muscle disorders such as myotonic dystrophy and muscular dystrophy, making it an attractive target for therapeutic interventions aimed at improving muscle function. Additionally, STAC2 serves as a negative regulator of osteoclast formation by targeting the RANK signaling complex, which explains its role in bone biology. The protein contains multiple functional domains including proline-rich regions, zinc finger domains, and SH3 domains that facilitate its various protein-protein interactions in cellular signaling pathways.

What is the molecular weight and structure of the STAC2 protein?

STAC2 is a 411 amino acid protein with a calculated molecular weight of approximately 45 kDa. In Western blot applications, it is typically observed at 42-45 kDa. The protein contains several important structural domains that mediate its cellular functions. These include proline-rich regions, zinc finger domains, and SH3 (Src Homology 3) domains, which are crucial for STAC2's protein-protein interactions. Multiple studies have demonstrated that these domains, particularly the zinc finger and SH3 domains, are required for STAC2's interaction with proteins such as RANK in osteoclast signaling pathways.

What types of STAC2 antibodies are commercially available for research?

Several types of STAC2 antibodies are available for research applications. These include polyclonal antibodies raised predominantly in rabbits that recognize different epitopes of the STAC2 protein. Some antibodies specifically target the N-terminal region, while others recognize internal regions of human STAC2. According to market analysis, there are over 100 STAC2 antibodies across 20 different suppliers, with variations in applications, reactivity, and conjugation status. Most of these antibodies are unconjugated, though some may be available with various tags for specialized detection methods. The majority are validated for Western blot (WB), ELISA, and immunohistochemistry (IHC) applications, with some also suitable for immunoprecipitation (IP).

What are the recommended dilutions for different applications of STAC2 antibodies?

Optimal dilutions vary depending on the specific application and antibody:

For the PACO23482 antibody specifically, recommended dilutions are ELISA (1:2000-1:10000) and WB (1:500-1:3000). For the Proteintech 24274-1-AP antibody, recommended dilutions are WB (1:200-1:1000) and IHC (1:20-1:200). These ranges should be considered starting points, and researchers should optimize dilutions for their specific experimental conditions, antibody lots, and detection systems.

Which positive controls are recommended for validating STAC2 antibody experiments?

For Western blot applications, SH-SY5Y neuroblastoma cells have been validated to express detectable levels of STAC2 and can serve as a reliable positive control. For immunohistochemistry, human prostate hyperplasia tissue has been documented to show positive STAC2 staining when using appropriate antigen retrieval methods (preferably TE buffer at pH 9.0). When studying STAC2 in the context of RANK signaling pathways, RANKL-stimulated bone marrow-derived macrophages (BMMs) can serve as a physiologically relevant positive control, as STAC2 expression is induced following RANKL stimulation in these cells. Including these validated positive controls alongside experimental samples helps confirm antibody functionality and provides a reference point for comparing expression levels.

What species reactivity has been validated for commercial STAC2 antibodies?

Commercial STAC2 antibodies vary in their species reactivity profiles. Many antibodies have been validated specifically for detection of human STAC2 proteins. Some antibodies demonstrate broader cross-reactivity, recognizing STAC2 in mouse and rat samples as well. Certain antibodies from suppliers like Aviva Systems Biology claim reactivity with multiple species including human, mouse, rabbit, rat, bovine, dog, horse, and pig, though validation data for all these species may be limited. When selecting an antibody for research with non-human models, it's essential to carefully review the validation data for your specific species of interest and consider performing preliminary validation experiments before proceeding with larger studies.

How should samples be prepared for optimal detection of STAC2 in different applications?

Sample preparation methods vary significantly depending on the application:

For Western Blot:

• Extract proteins using lysis buffers containing appropriate protease inhibitors to prevent degradation

• Include phosphatase inhibitors if investigating phosphorylation states in the STAC2 signaling pathway

• Optimize protein loading (typically 20-50 μg of total protein per lane)

• Use reducing conditions as STAC2 antibodies are typically raised against reduced epitopes

For Immunohistochemistry:

• Formalin-fixed paraffin-embedded sections typically require antigen retrieval

• TE buffer at pH 9.0 is specifically recommended for STAC2 detection, though citrate buffer at pH 6.0 may serve as an alternative

• Optimize blocking conditions to minimize background (typically 5-10% normal serum)

For Immunoprecipitation:

• When studying STAC2 interactions (such as with RANK), use lysis conditions that preserve protein-protein interactions

• Consider the timing of stimulation (e.g., RANKL) before lysis, as some interactions are stimulation-dependent

• Use mild detergents and physiological salt concentrations to maintain interaction integrity

What methods can be used to validate the specificity of STAC2 antibodies?

Multiple complementary approaches should be employed to validate antibody specificity:

• Genetic validation: Compare antibody signals in wild-type versus STAC2 knockdown or knockout samples. In studies examining STAC2's role in osteoclast formation, siRNA-mediated knockdown of STAC2 resulted in enhanced osteoclast formation and increased NFATc1 expression, providing validation for antibody specificity in detecting functional STAC2 protein.

• Overexpression validation: Compare signals in cells with endogenous STAC2 levels versus those overexpressing STAC2. BMMs overexpressing STAC2 showed decreased NFATc1 and Atp6v0d2 protein levels after RANKL stimulation, confirming antibody specificity.

• Multiple antibody approach: Use antibodies recognizing different epitopes of STAC2 to confirm consistent patterns of expression and localization.

• Preabsorption controls: Preincubate antibody with excess immunizing peptide to demonstrate signal elimination.

• Expected molecular weight verification: Confirm that detected bands align with the expected 42-45 kDa size of STAC2 protein.

How can STAC2 antibodies be used to study protein-protein interactions in signaling pathways?

STAC2 antibodies are valuable tools for studying protein-protein interactions through several methodologies:

• Co-immunoprecipitation (Co-IP): STAC2 antibodies can be used to pull down STAC2 along with its interacting partners. This approach has revealed that STAC2 interacts with RANK following RANKL stimulation in bone marrow-derived macrophages. When coupled with Western blotting using antibodies against suspected interacting proteins, Co-IP can confirm specific interactions.

• Domain mapping: Using STAC2 antibodies in combination with domain deletion mutants can identify which domains are critical for specific protein interactions. Research has shown that multiple domains of STAC2, including the proline-rich, zinc finger, and SH3 domains, are required for RANK interaction.

• Competitive binding studies: STAC2 antibodies can help elucidate how STAC2 influences other protein-protein interactions. For example, when STAC2 is overexpressed, the interaction between PLCγ2 and Btk/Tec significantly decreases while STAC2 still interacts with Btk/Tec, suggesting competitive binding mechanisms.

• Subcellular localization studies: Immunofluorescence with STAC2 antibodies can reveal where these interactions occur within cells. RANK and STAC2 have been observed to be recruited to lipid rafts following RANKL stimulation, which are specialized domains in RANK signal transduction.

What are common issues with STAC2 antibody Western blots and how can they be resolved?

Several challenges may arise when using STAC2 antibodies in Western blot applications:

• Weak or absent signal:

  • Increase protein loading (consider 30-50 μg total protein)

  • Optimize antibody concentration (try higher concentrations within the recommended range)

  • Extend primary antibody incubation time (overnight at 4°C often improves signal)

  • Try alternative antibodies targeting different epitopes of STAC2

  • Use more sensitive detection systems (enhanced chemiluminescence)

• Multiple bands or non-specific signals:

  • Increase blocking time and concentration (5% BSA or milk)

  • Optimize antibody dilution (sometimes more dilute antibody reduces non-specific binding)

  • Increase wash stringency (more frequent and longer washes)

  • Use freshly prepared buffers and reagents

  • Consider that STAC2 may undergo post-translational modifications resulting in multiple bands

• High background:

  • Use freshly prepared blocking solutions

  • Ensure thorough washing between antibody incubations

  • Dilute secondary antibody further

  • Shorten exposure time during imaging

• Inconsistent results between experiments:

  • Standardize protein extraction and quantification methods

  • Use consistent sample preparation and loading controls

  • Prepare larger batches of antibody dilutions to minimize preparation variables

How can I optimize STAC2 antibody performance in immunohistochemistry?

Successful immunohistochemical detection of STAC2 requires careful optimization:

• Antigen retrieval:

  • TE buffer at pH 9.0 is specifically recommended for STAC2 detection

  • As an alternative, citrate buffer at pH 6.0 may be used

  • Optimize retrieval time and temperature for your specific tissue type

• Antibody dilution and incubation:

  • Start with the recommended range (1:20-1:200) and perform a dilution series

  • Consider extended incubation times (overnight at 4°C) for improved sensitivity

  • Use humidity chambers to prevent section drying

• Background reduction:

  • Implement stringent blocking with serum matching the species of the secondary antibody

  • Include 0.1-0.3% Triton X-100 in buffers for better antibody penetration

  • Consider using commercial background-reducing reagents

  • Include an endogenous peroxidase blocking step if using HRP-based detection

• Signal amplification:

  • For low abundance targets, consider tyramide signal amplification

  • Biotin-streptavidin systems can enhance detection sensitivity

  • Polymer-based detection systems often provide cleaner results than biotin-based methods

• Validation controls:

  • Always include a known positive control (human prostate hyperplasia tissue has been validated)

  • Include a negative control by omitting primary antibody

  • Consider using tissue from STAC2 knockdown models as specificity controls

How do I interpret and troubleshoot results when studying STAC2 interactions in the RANK signaling pathway?

When investigating STAC2's role in the RANK signaling pathway, several considerations can help interpret and troubleshoot results:

• Timing considerations:

  • STAC2 interaction with RANK occurs after RANKL stimulation, so timing of cellular harvesting is critical

  • Conduct time-course experiments to capture transient interactions and signaling events

  • The phosphorylation state of interacting proteins (like PLCγ2) may change rapidly and require precise timing

• Interaction validation:

  • Confirm interactions using both forward and reverse co-immunoprecipitation

  • Validate interactions using complementary methods (e.g., proximity ligation assay)

  • Consider that some interactions may be indirect via larger signaling complexes

• Domain-specific effects:

  • Research shows that zinc finger and SH3 domains of STAC2 are critical for inhibiting osteoclast formation, while proline-rich deletion mutants retain this function

  • Use domain deletion mutants to verify function-specific interactions

  • Compare wild-type and mutant STAC2 effects on downstream signaling components

• Subcellular localization:

  • RANK and STAC2 are recruited to lipid rafts after RANKL stimulation

  • Consider subcellular fractionation to isolate membrane rafts in addition to whole-cell lysates

  • Compare cytoplasmic versus membrane-associated pools of STAC2 and interacting partners

• Competition mechanisms:

  • STAC2 overexpression decreases the interaction between PLCγ2 and Btk/Tec while maintaining Btk/Tec interaction

  • Titrate expression levels to understand dose-dependent effects on competing interactions

  • Analyze both positive and negative regulatory effects on signaling complex formation

How can STAC2 antibodies be used in advanced muscle biology research?

STAC2 antibodies enable sophisticated investigations in muscle biology:

• Excitation-contraction coupling studies:

  • Immunofluorescence co-localization of STAC2 with DHPR and RyR components

  • Analysis of STAC2 expression and localization changes in muscle development and disease

  • Comparison of STAC2 distribution in different muscle fiber types

• Disease mechanism investigation:

  • Compare STAC2 expression, post-translational modifications, and localization in healthy versus diseased muscle (myotonic dystrophy and muscular dystrophy)

  • Examine STAC2 interactions with calcium handling machinery in disease models

  • Correlate STAC2 expression patterns with clinical severity in patient samples

• Therapeutic screening:

  • Use STAC2 antibodies to validate target engagement of compounds designed to modulate excitation-contraction coupling

  • Monitor STAC2 expression and localization changes in response to therapeutic interventions

  • Develop cell-based assays using STAC2 antibodies for high-throughput drug screening

• Structural biology integration:

  • Combine STAC2 antibody data with structural information about DHPR-RyR complexes

  • Use epitope-specific antibodies to probe accessibility of different STAC2 domains in intact muscle

  • Correlate antibody-based detection with electron microscopy studies of triad junctions

What cutting-edge methodologies integrate STAC2 antibodies with other research techniques?

Several advanced methodologies can be combined with STAC2 antibodies:

• Proximity-based protein interaction detection:

  • Proximity ligation assays (PLA) can visualize and quantify STAC2 interactions with RANK, PLCγ2, or Btk/Tec in situ

  • FRET-based approaches using fluorescently-labeled STAC2 antibodies and antibodies against interacting proteins

  • BioID or APEX2 proximity labeling combined with STAC2 antibody validation of identified interactors

• Advanced imaging techniques:

  • Super-resolution microscopy (STORM, PALM, STED) with STAC2 antibodies can resolve nanoscale distribution

  • Live-cell imaging using membrane-permeable STAC2 antibody fragments to track dynamics

  • Expansion microscopy to physically enlarge specimens for improved visualization of STAC2 localization

• Multi-omics integration:

  • Combine STAC2 antibody-based proteomics (immunoprecipitation-mass spectrometry) with transcriptomics

  • Correlate STAC2 protein levels (detected by antibodies) with mRNA expression in single-cell multi-omics approaches

  • Integrate STAC2 antibody data with phosphoproteomic analyses of signaling networks

• In vivo applications:

  • Use STAC2 antibodies for intravital imaging in animal models

  • Develop therapeutic antibodies targeting STAC2 or its interaction partners

  • Antibody-based detection of STAC2 in patient-derived xenografts or organoids

How can STAC2 antibodies contribute to understanding bone disorders and developing therapeutics?

STAC2 antibodies can facilitate research into bone disorders and therapeutic development:

• Osteoclast differentiation studies:

  • Monitor endogenous STAC2 expression during osteoclast differentiation using validated antibodies

  • Compare STAC2 levels and localization in normal versus pathological osteoclast formation

  • Assess STAC2's role in mediating the effects of potential osteoporosis treatments

• Signaling pathway dissection:

  • Use STAC2 antibodies to track how the protein abolishes the RANK signaling complex containing Gab2 and PLCγ2

  • Investigate how STAC2 blocks the association between PLCγ2 and Btk/Tec in various bone disease models

  • Develop pathway-specific inhibitors targeting STAC2 interactions

• Therapeutic development:

  • Screen compounds that modulate STAC2 expression or interaction with RANK

  • Use STAC2 antibodies to validate target engagement of therapeutic candidates

  • Develop diagnostic applications to assess STAC2 levels as biomarkers of bone disease

• Translational research:

  • Compare STAC2 expression patterns in healthy versus diseased human bone samples

  • Correlate STAC2 levels or localization with clinical outcomes in bone disorders

  • Develop personalized medicine approaches based on STAC2 status in patient samples

How are AI and computational approaches enhancing antibody-based research for proteins like STAC2?

Emerging AI and computational approaches are transforming antibody-based research:

• Antibody design and optimization:

  • De novo antibody design using generative AI methods can create novel antibodies with improved specificity for STAC2

  • AI-based models can predict antibody-antigen binding and optimize complementarity determining regions (CDRs)

  • Computational approaches can design antibodies with reduced cross-reactivity to related proteins (STAC1, STAC3)

• Epitope prediction and targeting:

  • AI algorithms can predict optimal epitopes on STAC2 for antibody generation

  • Structure-based computational approaches can identify accessible epitopes in native protein conformations

  • In silico modeling can predict how antibodies recognize specific STAC2 domains (proline-rich, zinc finger, or SH3)

• Image analysis advancement:

  • Machine learning algorithms can quantify STAC2 immunostaining patterns in tissue sections

  • AI-based image analysis can detect subtle changes in STAC2 localization or expression levels

  • Deep learning approaches can integrate STAC2 staining with other markers for complex phenotypic profiling

• Virtual screening and in silico validation:

  • Computational tools like AlphaFold can predict STAC2 structure and potential antibody binding sites

  • Virtual screening can identify potential compounds that modulate STAC2-RANK interactions

  • In silico approaches complement and guide antibody-based experimental validation